SAN FRANCISCO–(BUSINESS WIRE)–Dignity Health, one of the five largest health systems in the U.S., today announced the findings of a nation-wide survey on the power of humankindness in health care and the perception of kindness in our society.Continue reading
Author Archive: AZBio
Advice to Innovate by: Feeling stuck? Make something better
Laura Huenneke, PhD, Vice President for Academic Affiars and Provost of Northern Arizona University, recently shared a great post for students titled “Feeling stuck? Make something better” on her NAU Blog.
It’s a message that can benefit all of us.Continue reading
VisionGate, Inc. Featured in Nature
VisionGate, Inc. was just featured in a Nature article in Oct. 2013. You can also read article on the Nature website.Continue reading
Eye Test Identifies Alzheimer’s
(BUSINESS WIRE)–Nov 15, 2013–Cognoptix disclosed today at the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) scientific meeting the strong results of a multi-site clinical trial of its SAPPHIRE II eye test, which is designed to identify Alzheimer’s Disease (AD) patients via a beta-amyloid (Ab) signature in their eyes.Continue reading
FTC Seeking Public Comment on Follow-On Biologics
The Federal Trade Commission (FTC) is seeking public comment on follow-on biologics.
- Press Release (November 8, 2013)
- Federal Register Notice (November 8, 2013)
- Filing a Public Comment (Deadline March 1, 2014)
In addition, the FTC will hold a public workshop on December 1oth.
The Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition
The Federal Trade Commission announces it will hold a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop will focus on a few key issues, inter alia:
- The potential impact of state regulations affecting competition.
- How regulations, if necessary, might be structured to facilitate competition while still protecting patient health and safety.
- How naming may affect competition.
- The experience of other countries with follow-on biologic competition.
The Federal Register Notice poses a series of questions about which the FTC seeks public comment. The FTC will take these comments into account in its examination of these topics.
Previous Biologics Workshops and Report:
Event Details
WHEN:
December 10, 2013 Time: 9am – 5pm
WHERE:
601 New Jersey Avenue, NW
Washington, DC
- Press Release (November 8, 2013)
- Federal Register Notice (November 8, 2013)
- Filing a Public Comment (Deadline March 1, 2014)
- Agenda (Coming Soon)
- Speaker Biographies (Coming Soon)
Learn more at http://www.ftc.gov/opp/workshops/biologics/#nj
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire via COMTEX/ — Amgen (AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.Continue reading
AZ Biotech in the spotlight at Governor’s Celebration of Innovation
The Arizona biotech community stepped into the spotlight at the 2013 Governor’s Celebration of Innovation Awards. Continue reading
Opportunity Alert: Faculty Research Scientist at St. Joe’s
The Heart and Lung Institute at St. Joseph’s Hospital and Medical Center is seeking an Faculty Research Scientist to join their team.Continue reading
Washington Update – November 2013
As a member of the Council of State Bioscience Associations, AZBio is pleased to share the following Washington Update for our AZBio Members.Continue reading